This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Dendreon's Aftermath

If Spectrum had real visibility into Fusilev's performance, especially vs. cheaper, generic leucovorin, it would give sales guidance. The company still chooses not to do so.

Zevalin sales totaled $8.4 million in the June quarter, up 42% sequentially. That's a nice turnaround, but I would also mention that Zevalin sales are now only just back to fourth-quarter levels. Spectrum continues to forecast "modest" Zevalin growth.

I'm a stubborn Spectrum bear and I see no reason yet to change my stance, particularly around the Fusilev vs. leucovorin issues. The main risk to the bear thesis is if Spectrum is successful in signing up enough physician practices to long-term Fusilev supply agreements to ensure the drug's continued growth even if or when generic leucovorin supplies are more fully replenished.

Spectrum mentioned these customer agreements on the call, so it's definitely worth noting if you're short the stock, and it's a reason to be optimistic if you're long.

One buy-side source whom I respect recently took a long position in Spectrum based on his belief that Fusilev sales will grow even with increased competition from cheaper leucovorin. I'll let him explain:

"We believe this business [Fusilev] will last and grow from accounts we have spoken to. Economic reasons play a part and also dosing error phenomenon is now playing a role in why doctors are fed up with switching back and forth from generic leucovorin… This is something doctors are telling us is a sticky issue in their practice," this buy-side investor tells me. He's long Spectrum but is not allowed to speak on the record to the media.

One drop-dead rule for biotech investing (any investing, actually) is to read closely a company's regulatory filings. What a company discloses to the Securities and Exchange Commission in an 8-K, 10-Q or 10-K is much more important than what's trumpeted in a press release.

Don't ignore press releases. Instead, compare the language and details scripted in the press release to what's disclosed in the SEC filings. If the two documents differ, i.e., if the press release leaves out salient yet less-than-positive details, you can infer that management may be more interested in spin than transparency.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMAG $21.01 -2.00%
DNDN $0.06 -6.02%
SPPI $4.29 -2.90%
SGEN $27.00 -0.15%
VRTX $80.64 1.20%


Chart of I:DJI
DOW 15,761.78 +101.60 0.65%
S&P 500 1,847.17 +18.09 0.99%
NASDAQ 4,309.7810 +42.9440 1.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs